Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Beazley H1 pre-tax profits fall, lowers FY premium growth guidance

(Sharecast News) - Specialist insurer Beazley reported a mixed set of first-half results on Wednesday, with solid premium growth offset by a sharp drop in profitability and a cut to full-year premium growth guidance. Insurance written premiums increased 2.04% year-on-year to $3.18bn, driven by continued expansion in its cyber and property lines, while pre-tax profits fell 45% to $502.5m, reflecting higher claims activity and a less favourable investment backdrop.

The FTSE 100-listed group's undiscounted combined ratio deteriorated to 84.9% from 80.7% a year earlier, and its insurance service result dropped 12% to $493.7m. Net assets per share improved 11% to 560p, as did net tangible assets per share, which came in at 536.1pp. Beazley also reported a 1% increase in net insurance written premiums to $2.6bn.

Beazley, which said in April that gross insurance written premium growth guidance remained at mid-single digits, also dropped its FY premium growth guidance to low-to-mid single digits, in order to reflect current market conditions.

However, analysts at Keefe, Bruyette & Woods noted: "Whilst the market will likely see today's top-line guidance change as disappointing, we think lower growth figures coupled with a strong Solvency 2 ratio support our view that investors should continue to expect Beazley to return material amounts of capital going forward."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.